Skip to main content

GordonMD Global Investments LP

13F filer · CIK 0002039349
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$207MU.S. long equity reported on 13F
Positions161 new · 1 closed
Net flow last quarter+$74.3MBuys minus sells
Top 10 positions weight83.9%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202616 positions
KYTXKyverna Therapeutics, Inc.$37.8M18.30%6.89%Not reportedQ4 2025
PYXSPyxis Oncology, Inc.$30.2M14.60%15.80%+143.2%Q4 2025
TSHATaysha Gene Therapies, Inc.$24.5M11.86%0.22%-2.0%Q4 2025
TEVATeva Pharmaceutical Industries Ltd$16.4M7.92%0.21%+91.1%Q4 2025
VIRVir Biotechnology, Inc.$13.8M6.67%0.80%-10.9%Q4 2025
ALLOAllogene Therapeutics, Inc.$11M5.33%1.53%+270.5%Q1 2026
CLDXCelldex Therapeutics, Inc.$10.4M5.04%0.36%+64.2%Q4 2025
EDITEditas Medicine, Inc.$10.1M4.90%3.20%NewQ2 2026
RAREUltragenyx Pharmaceutical Inc.$9.65M4.67%0.29%Not reportedQ4 2025
BLCOBausch & Lomb Corp$9.5M4.60%0.16%Not reportedQ4 2025
AMGNAmgen Inc$7.32M3.54%0.00%Not reportedQ4 2025
SRRKScholar Rock Holding Corp$7.29M3.53%0.11%Not reportedQ1 2026
SIONSionna Therapeutics, Inc.$5.98M2.89%0.30%Not reportedQ1 2026
INCYIncyte Corp$4.91M2.38%0.02%Not reportedQ4 2025
CRNXCrinetics Pharmaceuticals, Inc.$4.75M2.30%0.12%Not reportedQ4 2025
INSMINSMED Inc$3.05M1.47%0.01%Not reportedQ4 2025
Q1 2026Reported May 15, 202616 positions
KYTXKyverna Therapeutics, Inc.$36.6M25.51%7.01%-3.4%Q4 2025
TSHATaysha Gene Therapies, Inc.$22.2M15.47%0.26%-44.6%Q4 2025
VIRVir Biotechnology, Inc.$13.6M9.48%0.94%+63.2%Q4 2025
BLCOBausch & Lomb Corp$9.12M6.35%0.16%-6.5%Q4 2025
AMGNAmgen Inc$7.11M4.95%0.00%-12.9%Q4 2025
SRRKScholar Rock Holding Corp$6.51M4.54%0.11%NewQ1 2026
RAREUltragenyx Pharmaceutical Inc.$6.06M4.22%0.29%-12.2%Q4 2025
PYXSPyxis Oncology, Inc.$6.02M4.19%6.56%Not reportedQ4 2025
TEVATeva Pharmaceutical Industries Ltd$5.62M3.91%0.11%+63.4%Q4 2025
SIONSionna Therapeutics, Inc.$5.45M3.80%0.30%NewQ1 2026
CLDXCelldex Therapeutics, Inc.$5.4M3.76%0.26%Not reportedQ4 2025
INSMINSMED Inc$4.67M3.26%0.01%Not reportedQ4 2025
CRNXCrinetics Pharmaceuticals, Inc.$4.61M3.21%0.12%-43.3%Q4 2025
INCYIncyte Corp$4.08M2.84%0.02%-20.6%Q4 2025
ALLOAllogene Therapeutics, Inc.$3.49M2.43%0.58%NewQ1 2026
TARSTarsus Pharmaceuticals, Inc.$2.99M2.09%0.10%-36.0%Q4 2025
Q4 2025Reported Feb 17, 202613 positions
KYTXKyverna Therapeutics, Inc.$41.3M29.60%7.27%NewQ4 2025
TEVATeva Pharmaceutical Industries Ltd$24M17.22%0.07%NewQ4 2025
BLCOBausch & Lomb Corp$10.5M7.51%0.17%NewQ4 2025
CRNXCrinetics Pharmaceuticals, Inc.$10.4M7.48%0.23%NewQ4 2025
AMGNAmgen Inc$7.6M5.45%0.00%NewQ4 2025
RAREUltragenyx Pharmaceutical Inc.$7.57M5.43%0.34%NewQ4 2025
TSHATaysha Gene Therapies, Inc.$7.32M5.25%0.47%NewQ4 2025
VIRVir Biotechnology, Inc.$5.61M4.02%0.67%NewQ4 2025
TARSTarsus Pharmaceuticals, Inc.$5.46M3.91%0.16%NewQ4 2025
INCYIncyte Corp$5.38M3.86%0.03%NewQ4 2025
INSMINSMED Inc$4.98M3.57%0.01%NewQ4 2025
PYXSPyxis Oncology, Inc.$4.74M3.40%6.58%NewQ4 2025
CLDXCelldex Therapeutics, Inc.$4.63M3.32%0.26%NewQ4 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.